call Toll Free (US/Canada) : +1 866 658 6826 | call +1 425 320 4776 | call (UK) : +44 1865 60 0662 | email info(@)blueweaveconsulting.com
Home | About Us | Career | Services | Blog | Contact Us
Blueweave
Asia Pacific Multiple Sclerosis Drugs Market
Inquire Before Buying Request for Sample

Asia Pacific Multiple Sclerosis Drugs Market

Home Healthcare And Pharmaceutical Asia Pacific Multiple Sclerosis Drugs Market

SPECIAL OFFER : 25% Super Discount For All !

Asia Pacific Multiple Sclerosis Drugs Market, By Disease Type (Relapsing-Remitting Multiple Sclerosis (RRMS), Secondary Progressive Multiple Sclerosis (SPMS), Primary Progressive Multiple Sclerosis (PPMS), Severe Relapsing-Remitting Multiple Sclerosis (RES)); By Treatment (Preventive Therapies, Abortive Therapies/Treatment of Acute Exacerbations, Symptomatic Therapies); By Drug Type (Branded, Generic); By End User (Hospital & Clinics, Diagnostic Laboratories); By Country (China, India, Japan, South Korea, Australia & New Zealand, Indonesia, Malaysia, Singapore, Vietnam, Rest of APAC), Competitive Landscape & Forecast, 2019–2029

  • Published Date: November 2023
  • Report ID: BWC23912
  • Available Format: PDF
  • Page: 200

Report Overview

Increasing incidence of multiple sclerosis, growing awareness and diagnosis rates, expanding healthcare infrastructure, and advancements in drug therapies. Rising healthcare expenditure and a large patient population contribute to the growth of Asia-Pacific Multiple Sclerosis Drugs Market during the forecast period between 2023 and 2029.

Asia-Pacific Multiple Sclerosis Drugs Market – Industry Trends & Forecast Report, 2029

Asia-Pacific multiple sclerosis drugs market size was estimated at USD 4.09 billion in 2022. During the forecast period between 2023 and 2029, the size of Asia-Pacific multiple sclerosis drugs market is projected to grow at a CAGR of 8.65% reaching a value of USD 6.72 billion by 2029. Asia-Pacific multiple sclerosis drugs market is influenced by several key factors. A rising incidence of multiple sclerosis in the region drives market growth. Also, increased awareness and early diagnosis contribute to higher demand for MS drugs. Advancements in healthcare infrastructure expanded access to healthcare services, and government initiatives supporting neurology research and treatment further boosted the market. Collaboration between pharmaceutical companies and research institutions fosters innovation in drug development. Further, the growing aging population and changing lifestyles increase the patient pool, creating a sustained demand for multiple sclerosis drugs in the Asia-Pacific region.

Asia Pacific Multiple Sclerosis Drugs Market

Multiple Sclerosis Drugs - Overview

Multiple sclerosis (MS) drugs aim to manage the chronic autoimmune disease that affects the central nervous system. They fall into several categories, including disease-modifying therapies (DMTs), which slow the progression of MS and reduce relapses. Common DMTs include interferons, oral medications like fingolimod, and monoclonal antibodies such as ocrelizumab. Symptomatic treatments alleviate specific MS symptoms, like muscle spasms and fatigue. These drugs can improve a patient's quality of life but don't alter the course of the disease. A comprehensive approach to MS management typically combines DMTs and symptomatic treatments, tailored to each patient's specific needs and disease progression.

Asia-Pacific Multiple Sclerosis Market

Growth Drivers

Innovative Telemedicine Initiatives

Asia-Pacific multiple sclerosis drugs market is experiencing a unique growth driver through the rapid adoption of innovative telemedicine initiatives. As healthcare systems and technology infrastructure continue to advance in the region, telemedicine is enhancing accessibility to specialist care for multiple sclerosis patients, bridging geographical gaps, and improving treatment outcomes. This approach not only facilitates early diagnosis and treatment but also enables continuous monitoring and personalized care, driving demand for MS drugs. Further, it reduces the burden on in-person healthcare visits, making treatment more convenient for patients and boosting the market's expansion across the Asia-Pacific region.

Restraints

Limited Accessibility to Advanced Treatment Options

Asia-Pacific multiple sclerosis drugs market faces a unique restraint in the form of limited accessibility to advanced treatment options. While the region's growing prevalence of multiple sclerosis demands effective pharmaceutical solutions, disparities in healthcare infrastructure and distribution networks hinder patients' access to cutting-edge medications. Varied regulations, economic disparities, and cultural factors contribute to the challenge of ensuring equitable drug availability across the diverse Asia-Pacific landscape. Overcoming these accessibility barriers remains a pivotal concern for both pharmaceutical companies and healthcare providers seeking to address the increasing burden of multiple sclerosis in the region.

Impact of COVID-19 on Asia-Pacific Multiple Sclerosis Drugs Market

Asia-Pacific multiple sclerosis drugs market significantly shifts due to the COVID-19 pandemic. The market faced disruptions in supply chains, delayed clinical trials, and altered patient care dynamics, impacting drug availability and treatment continuity. Telemedicine and home-based treatments gained prominence, while healthcare systems adapted to new safety measures. Despite these challenges, the market showed resilience, with increased research and development efforts to address the unique needs of multiple sclerosis patients in the Asia-Pacific region. The pandemic underscored the importance of adaptable healthcare strategies and accelerated digital transformations in the industry.

Asia-Pacific Multiple Sclerosis Drugs Market

Segmental Coverage

Asia-Pacific Multiple Sclerosis Drugs Market – By Disease Type

Based on disease type, Asia-Pacific multiple sclerosis drugs market is divided into Relapsing-Remitting Multiple Sclerosis (RRMS), Secondary Progressive Multiple Sclerosis (SPMS), Primary Progressive Multiple Sclerosis (PPMS), Severe Relapsing-Remitting Multiple Sclerosis (RES) segments. Relapsing-Remitting Multiple Sclerosis (RRMS) is the largest disease type, which encompasses a significant portion of the market. RRMS is a common form of multiple sclerosis, characterized by periods of symptom relapse and remission. This segment represents a substantial patient population in the region, driving the demand for drugs and treatments aimed at managing and alleviating the condition's symptoms. While other segments like Secondary Progressive Multiple Sclerosis (SPMS), Primary Progressive Multiple Sclerosis (PPMS), and Severe Relapsing-Remitting Multiple Sclerosis (RES) also play vital roles, RRMS remains the dominant focus in the Asia-Pacific multiple sclerosis drug market.

Asia-Pacific Multiple Sclerosis Drugs Market – By Treatment

By treatment, Asia-Pacific multiple sclerosis drugs market is divided into Preventive Therapies, Abortive Therapies/Treatment of Acute Exacerbations, and Symptomatic Therapies segments. Preventive Therapies constitute the largest segment and they aim at reducing the frequency and severity of multiple sclerosis (MS) relapses, making them a pivotal component of managing the disease. They include disease-modifying drugs that work to slow down the progression of MS and reduce inflammation. This segment's prominence reflects the growing importance of long-term management and the need to prevent MS exacerbations, ultimately improving the quality of life for patients in the Asia-Pacific region.

Asia Pacific Multiple Sclerosis Drugs Market Size

Asia-Pacific Multiple Sclerosis Drugs Market – By Drug Type

By drug type, Asia-Pacific multiple sclerosis drugs market is divided into Branded and Generic segments. The branded segment comprises patented medications developed by pharmaceutical companies, often with higher prices due to research and development costs. In contrast, the Generic segment includes lower-cost alternatives once patents expire, offering more affordable treatment options. The market's largest segment can vary over time due to factors like patent expirations and the introduction of new medications, but both segments play crucial roles in addressing the healthcare needs of multiple sclerosis patients in the region.

Asia-Pacific Multiple Sclerosis Drugs Market – By End User

By end user, Asia-Pacific multiple sclerosis drugs market is divided into Hospital and Clinics, and Diagnostic Laboratories segments. These segments play pivotal roles in the diagnosis and treatment of multiple sclerosis within the region. Hospitals and Clinics offer essential medical care and therapeutic services to patients with multiple sclerosis, while Diagnostic Laboratories provide critical testing and diagnostic support. The market's largest segment can vary depending on factors such as regional healthcare infrastructure and patient preferences, with both segments contributing significantly to the overall management of multiple sclerosis in the Asia-Pacific region.

Asia-Pacific Multiple Sclerosis Drugs Market – By Country

Geographically, Asia-Pacific multiple sclerosis drugs market is divided into China, India, Japan, South Korea, Australia & New Zealand, Indonesia, Malaysia, Singapore, Vietnam, and Rest of APAC. China is the largest country in the Asia-Pacific multiple sclerosis drugs market. This vast and populous country represents a significant portion of the market due to its large population and growing healthcare infrastructure. China's increasing awareness of multiple sclerosis, coupled with a rising patient pool, has fueled demand for MS drugs. The nation's robust pharmaceutical industry and healthcare investments make it a key player in the market. While other countries in the region, such as India and Japan, also contribute significantly, China stands out as the dominant market segment in the rapidly evolving landscape of multiple sclerosis treatment in the Asia-Pacific region.

Competitive Landscape

Major players in the Asia-Pacific multiple sclerosis drugs market include Biogen, Sanofi, Novartis, Mitsubishi Tanabe Pharma, Merck Group, Sun Pharmaceutical Industries Ltd, Teva Pharmaceutical Industries, Sawai Pharmaceutical Co., Ltd, Meiji Seika Pharma Co., Ltd, and LG Chem Life Sciences. To grow their market share, these companies are also focusing on investing in innovations, collaborations, and expansions.

Scope of the Report

Attributes

Details

Years Considered

Historical Data – 2019–2022

Base Year – 2022

Estimated Year – 2023

Forecast Period – 2023–2029

Facts Covered

Revenue in USD Million

Market Coverage

China, India, Japan, South Korea, Australia & New Zealand, Indonesia, Malaysia, Singapore, Vietnam, Rest of APAC

Product/ Service Segmentation

Disease Type, Treatment, Drug Type, End-User, Country

Key Players

Biogen, Sanofi, Novartis, Mitsubishi Tanabe Pharma, Merck Group, Sun Pharmaceutical Industries Ltd, Teva Pharmaceutical Industries, Sawai Pharmaceutical Co., Ltd, Meiji Seika Pharma Co., Ltd, LG Chem Life Sciences

 

By Disease Type

  • Relapsing-Remitting Multiple Sclerosis (RRMS)

  • Secondary Progressive Multiple Sclerosis (SPMS)

  • Primary Progressive Multiple Sclerosis (PPMS)

  • Severe Relapsing-Remitting Multiple Sclerosis (RES)

By Treatment

  • Preventive Therapies

  • Abortive Therapies/Treatment of Acute Exacerbations

  • Symptomatic Therapies

By Drug Type

  • Branded

  • Generic

By End User

  • Hospital and Clinics

  • Diagnostic Laboratories

By Country

  • China

  • India

  • Japan

  • South Korea

  • Australia & New Zealand

  • Indonesia

  • Malaysia

  • Singapore

  • Vietnam

  • Rest of APAC

  1. Research Framework
    1. Research Objective
    2. Product Overview
    3. Market Segmentation
  2. Executive Summary
  3. Asia-Pacific Multiple Sclerosis Drugs Market Insights
    1. Industry Value Chain Analysis
    2. DROC Analysis
      1. Growth Drivers
        1. Increasing awareness about multiple sclerosis
        2. Increasing number of prospective pipeline drug development projects
      2. Restraints
        1. High treatment expenditure
        2. Limited access to high-cost therapies
      3. Opportunity
        1. Increasing demand of branded drugs
        2. Rapid advancements in the healthcare industry
      4. Challenges
        1. Lack of diagnosis and awareness
    3. Technological Advancements/Recent Developments
    4. Regulatory Framework
    5. Porter’s Five Forces Analysis
      1. Bargaining Power of Suppliers
      2. Bargaining Power of Buyers
      3. Threat of New Entrants
      4. Threat of Substitutes
      5. Intensity of Rivalry
  4. Asia-Pacific Multiple Sclerosis Drugs Market Overview
    1. Market Size & Forecast by Value & Volume, 2019–2029
      1. By Value (USD Million)
    2. Market Share & Forecast
      1. By Disease Type
        1. Relapsing–Remitting Multiple Sclerosis (RRMS)
        2. Secondary Progressive Multiple Sclerosis (SPMS)
        3. Primary Progressive Multiple Sclerosis (PPMS)
        4. Severe Relapsing–Remitting Multiple Sclerosis (RES)
      2. By Treatment
        1. Preventive Therapies
        2. Abortive Therapies/Treatment of Acute Exacerbations
        3. Symptomatic Therapies
      3. By Drug Type
        1. Branded
        2. Generic
      4. By End User
        1. Hospital and Clinics
        2. Diagnostic Laboratories
        3. Others
      5. By Country
        1. China
        2. India
        3. Japan
        4. South Korea
        5. Australia & New Zealand
        6. Indonesia
        7. Malaysia
        8. Singapore
        9. Vietnam
        10. Rest of APAC
  5. China Multiple Sclerosis Drugs Market Overview
    1. Market Size & Forecast by Value & Volume, 2019–2029
      1. By Value (USD Million)
    2. Market Share & Forecast
      1. By Disease Type
      2. By Treatment
      3. By Drug Type
      4. By End User
  6. India Multiple Sclerosis Drugs Market Overview
    1. Market Size & Forecast by Value & Volume, 2019–2029
      1. By Value (USD Million)
    2. Market Share & Forecast
      1. By Disease Type
      2. By Treatment
      3. By Drug Type
      4. By End User
  7. Japan Multiple Sclerosis Drugs Market Overview
    1. Market Size & Forecast by Value & Volume, 2019–2029
      1. By Value (USD Million)
    2. Market Share & Forecast
      1. By Disease Type
      2. By Treatment
      3. By Drug Type
      4. By End User
  8. South Korea Multiple Sclerosis Drugs Market Overview
    1. Market Size & Forecast by Value & Volume, 2019–2029
      1. By Value (USD Million)
    2. Market Share & Forecast
      1. By Disease Type
      2. By Treatment
      3. By Drug Type
      4. By End User
  9. Australia & New Zealand Multiple Sclerosis Drugs Market Overview
    1. Market Size & Forecast by Value & Volume, 2019–2029
      1. By Value (USD Million)
    2. Market Share & Forecast
      1. By Disease Type
      2. By Treatment
      3. By Drug Type
      4. By End User
  10. Indonesia Multiple Sclerosis Drugs Market Overview
    1. Market Size & Forecast by Value & Volume, 2019–2029
      1. By Value (USD Million)
    2. Market Share & Forecast
      1. By Disease Type
      2. By Treatment
      3. By Drug Type
      4. By End User
  11. Malaysia Multiple Sclerosis Drugs Market Overview
    1. Market Size & Forecast by Value & Volume, 2019–2029
      1. By Value (USD Million)
    2. Market Share & Forecast
      1. By Disease Type
      2. By Treatment
      3. By Drug Type
      4. By End User
  12. Singapore Multiple Sclerosis Drugs Market Overview
    1. Market Size & Forecast by Value & Volume, 2019–2029
      1. By Value (USD Million)
    2. Market Share & Forecast
      1. By Disease Type
      2. By Treatment
      3. By Drug Type
      4. By End User
  13. Vietnam Multiple Sclerosis Drugs Market Overview
    1. Market Size & Forecast by Value & Volume, 2019–2029
      1. By Value (USD Million)
    2. Market Share & Forecast
      1. By Disease Type
      2. By Treatment
      3. By Drug Type
      4. By End User
  14. Rest of APAC Multiple Sclerosis Drugs Market Overview
    1. Market Size & Forecast by Value & Volume, 2019–2029
      1. By Value (USD Million)
    2. Market Share & Forecast
      1. By Disease Type
      2. By Treatment
      3. By Drug Type
      4. By End User
  15. Competitive Landscape
    1. List of Key Players and Their Offerings
    2. Asia-Pacific Multiple Sclerosis Drugs Company Market Share Analysis, 2022
    3. Competitive Benchmarking, By Operating Parameters
    4. Key Strategic Development (Mergers, Acquisitions, Partnerships, etc.)
  16. Impact of Covid-19 on Asia-Pacific Multiple Sclerosis Drugs Market
  17. Company Profile (Company Overview, Financial Matrix, Competitive landscape, Key Personnel, Key Competitors, Contact Address, Strategic Outlook and SWOT Analysis)
    1. Biogen
    2. Sanof
    3. Novartis
    4. Mitsubishi Tanabe Pharma
    5. Merck Group
    6. Sun Pharmaceutical Industries Ltd
    7. Teva Pharmaceutical Industries
    8. Sawai Pharmaceutical Co., Ltd
    9. Meiji Seika Pharma Co., Ltd
    10. LG Chem Life Sciences
    11. Other Prominent Players
  18. Key Strategic Recommendations
  19. Research Methodology
    1. Qualitative Research
      1. Primary & Secondary Research
    2. Quantitative Research
    3. Market Breakdown & Data Triangulation
      1. Secondary Research
      2. Primary Research
    4. Breakdown of Primary Research Respondents, By Region
    5. Assumption & Limitation

 

*Financial information of non-listed companies will be provided as per availability

**The segmentation and the companies are subjected to modifications based on in-depth secondary for the final deliverable

 

List of Figures

 

Figure 1   Asia-Pacific Multiple Sclerosis Drugs Market Segmentation

Figure 2   Asia-Pacific Multiple Sclerosis Drugs Market Value Chain Analysis

Figure 3   Company Market Share Analysis, 2022

Figure 4   Asia-Pacific Multiple Sclerosis Drugs Market Size, By Value (USD Billion), 2019–2029

Figure 5   Asia-Pacific Multiple Sclerosis Drugs Market Share, By Disease Type, By Value, 2019–2029

Figure 6   Asia-Pacific Multiple Sclerosis Drugs Market Share, By Treatment, By Value, 2019–2029

Figure 7   Asia-Pacific Multiple Sclerosis Drugs Market Share, By Drug Type, By Value, 2019–2029

Figure 8   Asia-Pacific Multiple Sclerosis Drugs Market Share, By End User, By Value, 2019–2029

Figure 9   Asia-Pacific Multiple Sclerosis Drugs Market Share, By Country, By Value, 2019–2029

Figure 10 China Multiple Sclerosis Drugs Market Size, By Value (USD Billion), 2019–2029

Figure 11   China Multiple Sclerosis Drugs Market Share, By Disease Type, By Value, 2019–2029

Figure 12   China Multiple Sclerosis Drugs Market Share, By Treatment, By Value, 2019–2029

Figure 13   China Multiple Sclerosis Drugs Market Share, By Drug Type, By Value, 2019–2029

Figure 14 China Multiple Sclerosis Drugs Market Share, By End User, By Value, 2019–2029

Figure 15    India Multiple Sclerosis Drugs Market Size, By Value (USD Billion), 2019–2029

Figure 16    India Multiple Sclerosis Drugs Market Share, By Disease Type, By Value, 2019–2029

Figure 17    India Multiple Sclerosis Drugs Market Share, By Treatment, By Value, 2019–2029

Figure 18    India Multiple Sclerosis Drugs Market Share, By Drug Type, By Value, 2019–2029

Figure 19    India Multiple Sclerosis Drugs Market Share, By End User, By Value, 2019–2029

Figure 20    Japan Multiple Sclerosis Drugs Market Size, By Value (USD Billion), 2019–2029

Figure 21    Japan Multiple Sclerosis Drugs Market Share, By Disease Type, By Value, 2019–2029

Figure 22    Japan Multiple Sclerosis Drugs Market Share, By Treatment, By Value, 2019–2029

Figure 23    Japan Multiple Sclerosis Drugs Market Share, By Drug Type, By Value, 2019–2029

Figure 24    Japan Multiple Sclerosis Drugs Market Share, By End User, By Value, 2019–2029

Figure 25    South Korea Multiple Sclerosis Drugs Market Size, By Value (USD Billion), 2019–2029

Figure 26    South Korea Multiple Sclerosis Drugs Market Share, By Disease Type, By Value, 2019–2029

Figure 27    South Korea Multiple Sclerosis Drugs Market Share, By Treatment, By Value, 2019–2029

Figure 28    South Korea Multiple Sclerosis Drugs Market Share, By Drug Type, By Value, 2019–2029

Figure 29    South Korea Multiple Sclerosis Drugs Market Share, By End User, By Value, 2019–2029

Figure 30    Australia & New Zealand Multiple Sclerosis Drugs Market Size, By Value (USD Billion), 2019–2029

Figure 31    Australia & New Zealand Multiple Sclerosis Drugs Market Share, By Disease Type, By Value, 2019–2029

Figure 32    Australia & New Zealand Multiple Sclerosis Drugs Market Share, By Treatment, By Value, 2019–2029

Figure 33 Australia & New Zealand Multiple Sclerosis Drugs Market Share, By Drug Type, By Value, 2019–2029

Figure 34    Australia & New Zealand Multiple Sclerosis Drugs Market Share, By End User, By Value, 2019–2029

Figure 35    Indonesia Multiple Sclerosis Drugs Market Size, By Value (USD Billion), 2019–2029

Figure 36    Indonesia Multiple Sclerosis Drugs Market Share, By Disease Type, By Value, 2019–2029

Figure 37    Indonesia Multiple Sclerosis Drugs Market Share, By Treatment, By Value, 2019–2029

Figure 38    Indonesia Multiple Sclerosis Drugs Market Share, By Drug Type, By Value, 2019–2029

Figure 39    Indonesia Multiple Sclerosis Drugs Market Share, By End User, By Value, 2019–2029

Figure 40    Malaysia Multiple Sclerosis Drugs Market Size, By Value (USD Billion), 2019–2029

Figure 41    Malaysia Multiple Sclerosis Drugs Market Share, By Disease Type, By Value, 2019–2029

Figure 42    Malaysia Multiple Sclerosis Drugs Market Share, By Treatment, By Value, 2019–2029

Figure 43    Malaysia Multiple Sclerosis Drugs Market Share, By Drug Type, By Value, 2019–2029

Figure 44     Malaysia Multiple Sclerosis Drugs Market Share, By End User, By Value, 2019–2029

Figure 45    Singapore Multiple Sclerosis Drugs Market Size, By Value (USD Billion), 2019–2029

Figure 46    Singapore Multiple Sclerosis Drugs Market Share, By Disease Type, By Value, 2019–2029

Figure 47    Singapore Multiple Sclerosis Drugs Market Share, By Treatment, By Value, 2019–2029

Figure 48    Singapore Multiple Sclerosis Drugs Market Share, By Drug Type, By Value, 2019–2029

Figure 49    Singapore Multiple Sclerosis Drugs Market Share, By End User, By Value, 2019–2029

Figure 50    Vietnam Multiple Sclerosis Drugs Market Size, By Value (USD Billion), 2019–2029

Figure 51    Vietnam Multiple Sclerosis Drugs Market Share, By Disease Type, By Value, 2019–2029

Figure 52    Vietnam Multiple Sclerosis Drugs Market Share, By Treatment, By Value, 2019–2029

Figure 53    Vietnam Multiple Sclerosis Drugs Market Share, By Drug Type, By Value, 2019–2029

Figure 54    Vietnam Multiple Sclerosis Drugs Market Share, By End User, By Value, 2019–2029

Figure 55    Rest of Asia-Pacific Multiple Sclerosis Drugs Market Size, By Value (USD Billion), 2019–2029

Figure 56    Rest of Asia-Pacific Multiple Sclerosis Drugs Market Share, By Disease Type, By Value, 2019–2029

Figure 57    Rest of Asia-Pacific Multiple Sclerosis Drugs Market Share, By Treatment, By Value, 2019–2029

Figure 58     Rest of Asia-Pacific Multiple Sclerosis Drugs Market Share, By Drug Type, By Value, 2019–2029

Figure 59    Rest of Asia-Pacific Multiple Sclerosis Drugs Market Share, By End User, By Value, 2019–2029

 

List of Tables

 

Table 1      Asia-Pacific Multiple Sclerosis Drugs Market Size, By Disease Type, By Value, 2019–2029

Table 2      Asia-Pacific Multiple Sclerosis Drugs Market Size, By Treatment, By Value, 2019–2029

Table 3      Asia-Pacific Multiple Sclerosis Drugs Market Size, By Drug Type, By Value, 2019–2029

Table 4      Asia-Pacific Multiple Sclerosis Drugs Market Size, By End User, By Value, 2019–2029

Table 5      Asia-Pacific Multiple Sclerosis Drugs Market Size, By Country, By Value, 2019–2029

Table 6      China Multiple Sclerosis Drugs Market Size, By Disease Type, By Value, 2019–2029

Table 7      China Multiple Sclerosis Drugs Market Size, By Treatment, By Value, 2019–2029

Table 8      China Multiple Sclerosis Drugs Market Size, By Drug Type, By Value, 2019–2029

Table 9      China Multiple Sclerosis Drugs Market Size, By End User, By Value, 2019–2029

Table 10    India Multiple Sclerosis Drugs Market Size, By Disease Type, By Value, 2019–2029

Table 11    India Multiple Sclerosis Drugs Market Size, By Treatment, By Value, 2019–2029

Table 12    India Multiple Sclerosis Drugs Market Size, By Drug Type, By Value, 2019–2029

Table 13    India Multiple Sclerosis Drugs Market Size, By End User, By Value, 2019–2029

Table 14    Japan Multiple Sclerosis Drugs Market Size, By Disease Type, By Value, 2019–2029

Table 15    Japan Multiple Sclerosis Drugs Market Size, By Treatment, By Value, 2019–2029

Table 16    Japan Multiple Sclerosis Drugs Market Size, By Drug Type, By Value, 2019–2029

Table 17    Japan Multiple Sclerosis Drugs Market Size, By End User, By Value, 2019–2029

Table 18    South Korea Multiple Sclerosis Drugs Market Size, By Disease Type, By Value, 2019–2029

Table 19    South Korea Multiple Sclerosis Drugs Market Size, By Treatment, By Value, 2019–2029

Table 20    South Korea Multiple Sclerosis Drugs Market Size, By Drug Type, By Value, 2019–2029

Table 21    South Korea Multiple Sclerosis Drugs Market Size, By End User, By Value, 2019–2029

Table 22    Australia & New Zealand Multiple Sclerosis Drugs Market Size, By Disease Type, By Value, 2019–2029

Table 23    Australia & New Zealand Multiple Sclerosis Drugs Market Size, By Treatment, By Value, 2019–2029

Table 24    Australia & New Zealand Multiple Sclerosis Drugs Market Size, By Drug Type, By Value, 2019–2029

Table 25    Australia & New Zealand Multiple Sclerosis Drugs Market Size, By End User, By Value, 2019–2029

Table 26    Indonesia Multiple Sclerosis Drugs Market Size, By Disease Type, By Value, 2019–2029

Table 27    Indonesia Multiple Sclerosis Drugs Market Size, By Treatment, By Value, 2019–2029

Table 28    Indonesia Multiple Sclerosis Drugs Market Size, By Drug Type, By Value, 2019–2029

Table 29    Indonesia Multiple Sclerosis Drugs Market Size, By End User, By Value, 2019–2029

Table 30    Malaysia Multiple Sclerosis Drugs Market Size, By Disease Type, By Value, 2019–2029

Table 31    Malaysia Multiple Sclerosis Drugs Market Size, By Treatment, By Value, 2019–2029

Table 32    Malaysia Multiple Sclerosis Drugs Market Size, By Drug Type, By Value, 2019–2029

Table 33    Malaysia Multiple Sclerosis Drugs Market Size, By End User, By Value, 2019–2029

Table 34    Singapore Multiple Sclerosis Drugs Market Size, By Disease Type, By Value, 2019–2029

Table 35    Singapore Multiple Sclerosis Drugs Market Size, By Treatment, By Value, 2019–2029

Table 36    Singapore Multiple Sclerosis Drugs Market Size, By Drug Type, By Value, 2019–2029

Table 37    Singapore Multiple Sclerosis Drugs Market Size, By End User, By Value, 2019–2029

Table 38    Vietnam Multiple Sclerosis Drugs Market Size, By Disease Type, By Value, 2019–2029

Table 39    Vietnam Multiple Sclerosis Drugs Market Size, By Treatment, By Value, 2019–2029

Table 40    Vietnam Multiple Sclerosis Drugs Market Size, By Drug Type, By Value, 2019–2029

Table 41    Vietnam Multiple Sclerosis Drugs Market Size, By End User, By Value, 2019–2029

Table 42    Rest of Asia-Pacific Multiple Sclerosis Drugs Market Size, By Disease Type, By Value, 2019–2029

Table 43    Rest of Asia-Pacific Multiple Sclerosis Drugs Market Size, By Treatment, By Value, 2019–2029

Table 44    Rest of Asia-Pacific Multiple Sclerosis Drugs Market Size, By Drug Type, By Value, 2019–2029

Table 45    Rest of Asia-Pacific Multiple Sclerosis Drugs Market Size, By End User, By Value, 2019–2029

Table 47    Biogen Company Overview

Table 48    Biogen Financial Overview

Table 49    Sanof Company Overview

Table 50    Sanof Financial Overview

Table 51    Novartis Company Overview

Table 52    Novartis Financial Overview

Table 53    Mitsubishi Tanabe Pharma Company Overview

Table 54    Mitsubishi Tanabe Pharma Financial Overview

Table 55    Merck Group Company Overview

Table 56    Merck Group Financial Overview

Table 57    Sun Pharmaceutical Industries Ltd Company Overview

Table 58    Sun Pharmaceutical Industries Ltd Financial Overview

Table 59    Teva Pharmaceutical Industries Company Overview

Table 60    Teva Pharmaceutical Industries Financial Overview

Table 61    Sawai Pharmaceutical Co., Ltd Company Overview

Table 62    Sawai Pharmaceutical Co., Ltd Financial Overview

Table 63    Meiji Seika Pharma Co., Ltd Company Overview

Table 64    Meiji Seika Pharma Co., Ltd Financial Overview

Table 65    LG Chem Life Sciences Company Overview

Table 66    LG Chem Life Sciences Financial Overview

Market Segmentation

No data available
No data available

To request a free sample copy of this report, please complete the form below.

We value your investment and offer free customization with every report to fulfil your exact research needs.

This website is secure and your personal details are safe.

Frequently Asked Questions (FAQs):

Ans: Asia-Pacific Multiple Sclerosis Drugs Market size was estimated at USD 4.09 billion in 2022.
Ans: Asia-Pacific Multiple Sclerosis Drugs Market size is expected to grow at a CAGR of 8.65% during the forecast period between 2023 and 2029.
Ans: Asia-Pacific Multiple Sclerosis Drugs Market size is expected to reach a value of USD 6.72 billion by 2029.
Ans: Major factors driving the growth of the Asia-Pacific Multiple Sclerosis Drugs Market include increasing incidence of multiple sclerosis, growing awareness and diagnosis rates, expanding healthcare infrastructure, and advancements in drug therapies. Rising healthcare expenditure and a large patient population contribute to market growth.
Ans: Key players in the Asia-Pacific Multiple Sclerosis Drugs Market include Biogen, Sanofi, Novartis, Mitsubishi Tanabe Pharma, Merck Group, Sun Pharmaceutical Industries Ltd, Teva Pharmaceutical Industries, Sawai Pharmaceutical Co., Ltd, Meiji Seika Pharma Co., Ltd, and LG Chem Life Sciences.
Ans: The branded hold a higher market share in the Asia-Pacific Multiple Sclerosis Drugs Market by drug type.
Ans: China holds the highest market share in the Asia-Pacific Multiple Sclerosis Drugs Market.